Regeneron Pharmaceuticals (MEX:REGN) Change In Other Working Capital : MXN2,399 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Change In Other Working Capital?

Regeneron Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Mar. 2025 was MXN362 Mil. It means Regeneron Pharmaceuticals's Other Working Capital increased by MXN362 Mil from Dec. 2024 to Mar. 2025 .

Regeneron Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was MXN4,751 Mil. It means Regeneron Pharmaceuticals's Other Working Capital increased by MXN4,751 Mil from Dec. 2023 to Dec. 2024 .

Regeneron Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for Regeneron Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Change In Other Working Capital Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Other Working Capital

Get a 7-Day Free Trial

2,946.01

-2,465.78

631.67

643.32

4,750.93

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Other Working Capital	Get a 7-Day Free Trial															1,940.10	1,632.32	846.68	-442.14	362.11

Regeneron Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,399 Mil.

Regeneron Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

REGN:USA 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).